Sedoanaljezikler ve Antipsikotikler
Özet
Yoğun bakım ünitelerinde kritik hastaların konforunu sağlamak ve zararlı fizyolojik sonuçları önlemek için ağrı, anksiyete, ajitasyon ve deliryumun erken tespiti ve tedavisi büyük önem taşımaktadır. Ağrıya verilen stres yanıtı metabolizmayı ve oksijen tüketimini artırırken, doku oksijenizasyonunu bozup miyokardiyal oksijen ihtiyacını yükseltmektedir. Ağrı değerlendirmesinde hastanın beyanı altın standart olsa da iletişim kuramayan hastalarda Davranışsal Ağrı Ölçeği ve Yoğun Bakım Ağrı Gözlem Ölçeği gibi ölçekler kullanılır. Analjezide temel olarak morfin, fentanil, remifentanil gibi opioidlerin yanı sıra opioid ihtiyacını azaltmak için asetaminofen, gabapentin ve pregabalin gibi nonopioid ilaçlar ve adjuvanlar tercih edilir. Sedasyon yönetiminde ise GABA reseptörleri üzerinden etki gösteren benzodiazepinler (midazolam, lorazepam), propofol, alfa-2 agonist deksmedetomidin ve ketamin kullanılmaktadır. Sedasyon derinliğini belirlemek amacıyla RASS ve SAS gibi geçerli ölçekler kullanılarak aşırı sedasyon riski önlenmeye çalışılır. Yoğun bakımda sık karşılaşılan akut organik mental sendrom olan deliryumun tedavisinde ise haloperidol ve ketiapin, olanzapin gibi atipik antipsikotikler tercih edilir. Tüm bu sedoanaljezik ve antipsikotik ilaçların seçimi, hastanın yaşı, organ fonksiyonları ve klinik tablosuna göre bireyselleştirilmelidir.
In intensive care units, early detection and treatment of pain, anxiety, agitation, and delirium are of paramount importance to ensure patient comfort and prevent harmful physiological outcomes. The stress response to pain increases metabolism and oxygen consumption, while impairing tissue oxygenation and elevating myocardial oxygen demand. Although patient self-report is the gold standard for pain assessment, scales like the Behavioral Pain Scale and the Critical Care Pain Observation Tool are utilized for non-communicative patients. Opioids such as morphine, fentanyl, and remifentanil serve as the cornerstone of analgesia, while non-opioids and adjuvants like acetaminophen, gabapentin, and pregabalin are preferred to reduce opioid requirements. For sedation management, benzodiazepines acting on GABA receptors (midazolam, lorazepam), propofol, the alpha-2 agonist dexmedetomidine, and ketamine are employed. To prevent over-sedation, validated scales such as RASS and SAS are used to monitor sedation depth. In the treatment of delirium, an acute organic mental syndrome common in the ICU, haloperidol and atypical antipsychotics like quetiapine and olanzapine are preferred. Ultimately, the selection of sedoanalgesic and antipsychotic medications must be individualized based on patient age, organ functions, and clinical status.
Referanslar
Walder B, Tramèr MR. Analgesia and sedation in critically ill patients. Swiss Medical Weekly. 2004 12;134(23-24):333-46.
Park, J. M., & Kim, J. H., Assessment and treatment of pain in adult intensive care unit patients. Korean Journal of Critical Care Medicine,2014, 29(3), 147-159.
Payen JF, Bru O, Bosson JL, et al., Assessing pain in critically ill sedated patients by using a behavioral pain scale. Crit Care Med. 2001, 29(12):2258-63. doi: 10.1097/00003246-200112000-00004.
Gélinas C, Fillion L, Puntillo KA, et al., Validation of the critical-care pain observation tool in adult patients. Am J Crit Care. 2006, 15(4):420-7.
Karcioglu O, Topacoglu H, Dikme O, et al., A systematic review of the pain scales in adults: Which to use? Am J Emerg Med. 2018, 36(4):707-714. doi: 10.1016/j.ajem.2018.01.008.
Devlin JW, Skrobik Y, Gélinas C, et al., Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018, 46(9):e825-e873. doi: 10.1097/CCM.0000000000003299.
Redmond DE Jr, Krystal JH. Multiple mechanisms of withdrawal from opioid drugs. Annu Rev Neurosci. 1984;7:443-78. doi: 10.1146/annurev.ne.07.030184.002303.
https://www.uptodate.com/contents/pain-control-in-the-critically-ill-adult-patient. , 2021.
Paul D, Standifer KM, Inturrisi CE, et al., Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther. 1989, 251(2):477-83.
Aronoff, George R. Drug prescribing in renal failure. ACP Press, 2007.
Golightly, Larry K., et al. "Renal pharmacotherapy." Dosage Adjustment of Medications Eliminated by the Kidneys (2013).
Pauli-Magnus C, Hofmann U, Mikus G, et al., Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1999,14(4):903-9. doi: 10.1093/ndt/14.4.903.
Jamal JA, Joh J, Bastani B. Removal of morphine with the new high-efficiency and high-flux membranes during haemofiltration and haemodialfiltration. Nephrol Dial Transplant. 1998, 13(6):1535-7. doi: 10.1093/ndt/13.6.1535.
Joffe AM, Hallman M, Gélinas C, et al., Evaluation and treatment of pain in critically ill adults. Semin Respir Crit Care Med. 2013, 34(2):189-200. doi: 10.1055/s-0033-1342973.
Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000, 27(7):524-8. doi: 10.1046/j.1440-1681.2000.03290.x.
Coluzzi F, Caputi FF, Billeci D, et al., Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists. Ther Clin Risk Manag. 2020, 9;16:821-837. doi: 10.2147/TCRM.S262843.
https://www.uptodate.com/contents/hydromorphone, u.c. hydromorphone. 2021.
Mayes S, Ferrone M. Fentanyl HCl patient-controlled iontophoretic transdermal system for the management of acute postoperative pain. Ann Pharmacother. 2006, 40(12):2178-86. doi: 10.1345/aph.1H135.
Beathard GA, Urbanes A, Litchfield T, et al., The risk of sedation/analgesia in hemodialysis patients undergoing interventional procedures. Semin Dial. 2011, 24(1):97-103. doi: 10.1111/j.1525-139X.2011.00844.x.
Caraceni A, Hanks G, Kaasa S, et al., European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012, 13(2):e58-68. doi: 10.1016/S1470-2045(12)70040-2.
Bovill JG, Sebel PS, Blackburn CL, et al., The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. Anesthesiology. 1982, 57(6):439-443. DOI: 10.1097/00000542-198212000-00002.
Guignard B, Bossard AE, Coste C, et al., Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000, 93(2):409-17. doi: 10.1097/00000542-200008000-00019.
Schechter, Neil L., Charles B. Berde, and Myron Yaster, eds. Pain in infants, children, and adolescents. Lippincott Williams & Wilkins, 2003.
https://www.drugs.com/pro/naloxone.html 2021
Quibell, Rachel, Prommer, et al., Ketamine. Journal of Pain and Symptom Management, 2011, 3(41), 640-649.
Maher DP, Chen L, Mao J. Intravenous Ketamine Infusions for Neuropathic Pain Management: A Promising Therapy in Need of Optimization. Anesth Analg. 2017, 124(2):661-674. doi: 10.1213/ANE.0000000000001787.
Chincholkar M. Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth. 2018, 120(6):1315-1334. doi: 10.1016/j.bja.2018.02.066.
Pasero D, Sangalli F, Baiocchi M, et al., Experienced Use of Dexmedetomidine in the Intensive Care Unit: A Report of a Structured Consensus. Turk J Anaesthesiol Reanim. 2018, 46(3):176-183. doi: 10.5152/TJAR.2018.08058.
Mo Y, Zimmermann AE. Role of dexmedetomidine for the prevention and treatment of delirium in intensive care unit patients. Ann Pharmacother. 2013, 47(6):869-76. doi: 10.1345/aph.1AR708.
Linn DD, Loeser KC. Dexmedetomidine for Alcohol Withdrawal Syndrome. Ann Pharmacother. 2015, 49(12):1336-42. doi: 10.1177/1060028015607038.
Honey BL, Benefield RJ, Miller JL, et al., Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother. 2009, 43(9):1506-11. doi: 10.1345/aph.1M161.
Shehabi Y, Howe BD, Bellomo R, et al., ANZICS Clinical Trials Group and the SPICE III Investigators. Early Sedation with Dexmedetomidine in Critically Ill Patients. N Engl J Med. 2019, 27;380(26):2506-2517. doi: 10.1056/NEJMoa1904710.
Sichrovsky TC, Mittal S, Steinberg JS. Dexmedetomidine sedation leading to refractory cardiogenic shock. Anesth Analg. 2008, 106(6):1784-6. doi: 10.1213/ane.0b013e318172fafc.
Gommers D, Bakker J. Medications for analgesia and sedation in the intensive care unit: an overview. Crit Care. 2008;12 Suppl 3(Suppl 3):S4. doi: 10.1186/cc6150.
Ziegler WH, Schalch E, Leishman B, et al., Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br J Clin Pharmacol. 1983;16 Suppl 1(Suppl 1):63S-69S. doi: 10.1111/j.1365-2125.1983.tb02272.x.
Jacobi J, Fraser GL, Coursin DB, et al., Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002, 30(1):119-41. doi: 10.1097/00003246-200201000-00020.
Litchfield NB. Complications of Intravenous Diazepam - Adverse Psychological Reactions. (An assessment of 16,000 cases). Anesth Prog. 1980, 27(6):175-83.
Thurston TA, Williams CG, Foshee SL. Reversal of a paradoxical reaction to midazolam with flumazenil. Anesth Analg. 1996, 83(1):192. doi: 10.1097/00000539-199607000-00036.
Yahwak JA, Riker RR, Fraser GL, et al., Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. Pharmacotherapy. 2008, 28(8):984-91. doi: 10.1592/phco.28.8.984.
Barr J, Donner A. Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Crit Care Clin. 1995, 11(4):827-47.
Tanios MA, de Wit M, Epstein SK, et al., Perceived barriers to the use of sedation protocols and daily sedation interruption: a multidisciplinary survey. J Crit Care. 2009, 24(1):66-73. doi: 10.1016/j.jcrc.2008.03.037.
Carson SS, Kress JP, Rodgers JE, et al., A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med. 2006, 34(5):1326-32. doi: 10.1097/01.CCM.0000215513.63207.7F.
Diedrich DA, Brown DR. Analytic reviews: propofol infusion syndrome in the ICU. J Intensive Care Med. 2011, 26(2):59-72. doi: 10.1177/0885066610384195.
Roberts I, Sydenham E. Barbiturates for acute traumatic brain injury. Cochrane Database Syst Rev. 2012, 12;12(12):CD000033. doi: 10.1002/14651858.CD000033.pub2.
Hamele M, Stockmann C, Cirulis M, et al., Ventilator-Associated Pneumonia in Pediatric Traumatic Brain Injury. J Neurotrauma. 2016, 1;33(9):832-9. doi: 10.1089/neu.2015.4004.
Golden TR, Solnicky V, Wadeea R, et al., Pentobarbital-induced lactic acidosis following status epilepticus barbiturate coma. BMJ Case Rep. 2018, 22;2018:bcr2017223482. doi: 10.1136/bcr-2017-223482.
Sessler CN, Gosnell MS, Grap MJ, et al., The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002, 15;166(10):1338-44. doi: 10.1164/rccm.2107138.
Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. Crit Care Med. 1999, 27(7):1325-9. doi: 10.1097/00003246-199907000-00022.
Barr J, Fraser GL, Puntillo K, et al., American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013, 41(1):263-306. doi: 10.1097/CCM.0b013e3182783b72.
Minhas MA, Velasquez AG, Kaul A, et al., Effect of Protocolized Sedation on Clinical Outcomes in Mechanically Ventilated Intensive Care Unit Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Mayo Clin Proc. 2015, 90(5):613-23. doi: 10.1016/j.mayocp.2015.02.016.
Schuurmans MJ, Duursma SA, Shortridge-Baggett LM. Early recognition of delirium: review of the literature. J Clin Nurs. 2001, 10(6):721-9. doi: 10.1046/j.1365-2702.2001.00548.x.
Ely EW, Margolin R, Francis J, et al., Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001, 29(7):1370-9. doi: 10.1097/00003246-200107000-00012.
Bergeron N, Dubois MJ, Dumont M, et al., Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001, 27(5):859-64. doi: 10.1007/s001340100909.
Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999, 37(6):435-56. doi: 10.2165/00003088-199937060-00001.
Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med. 1994, 22(3):433-40. doi: 10.1097/00003246-199403000-00013.
Avent KM, DeVoss JJ, Gillam EM. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites. Chem Res Toxicol. 2006, 19(7):914-20. doi: 10.1021/tx0600090.
Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol. 1993, 13(2):128-32.
Lonergan E, Britton AM, Luxenberg J, et al., Antipsychotics for delirium. Cochrane Database Syst Rev. 2007, 18;(2):CD005594. doi: 10.1002/14651858.CD005594.pub2. Update in: Cochrane Database Syst Rev. 2018 Jun 18;6:CD005594.
